Maurizio Nicolelli
Analyst · William Blair
Thank you, Rohit. And thanks, everyone, for joining us this morning. I will provide insights into our financial performance for the third quarter and the first nine months of 2020, followed by our outlook for the business. As Rohit mentioned, our quarter was better than we expected as revenue was $241 million, up 7.7% sequentially on a constant currency basis. Adjusted EPS was $1.04 compared to $0.53 in the second quarter. All revenue growth numbers mentioned hereafter are on a constant currency basis. My discussion on year-over-year growth percentages or improvements will be excluding Health Integrated for 2019 for a true comparison with 2020 performance unless mentioned otherwise. For the quarter, we generated revenue of $241 million, down 3.1% year-over-year. This includes one-time COVID related pass-through revenue of $4.4 million. Sequentially, from the second quarter, revenue was up 7.7%. Revenue for the quarter was higher than the interim guidance we provided in September as we were able to fulfill almost 100% of demand. Revenue from our operations management business as defined by three reportable segments excluding analytics was $150.5 million, down 5.7% year-over-year. Sequentially, from the second quarter, revenue was up 6.1%. Insurance generated revenue of $87.8 million, down 3.9% year-over-year. This decline was driven largely by supply constraints in our field service business. Compared to Q2 of 2020, insurance revenue was up 7.1%. Healthcare continued its growth momentum, with revenue of $25.1 million, up 10.5% year-over-year. This growth was driven by the ramp-up of new client wins in 2019 in the area of clinical services. Emerging reported revenue of $37.6 million, which was a year-over-year decline of 17.3% due to the reduction in travel, transportation and logistics volumes, offset by increases in all other categories. Revenue was up 8% when comparing to the second quarter of this year. Analytics had revenue of $90.5 million, up 1.6% year-over-year. This growth was driven by higher volumes in the healthcare and insurance industry verticals. Sequentially, from the second quarter of this year, revenue was up 10.4%. Our SG&A expenses declined by 130 basis points year-over-year to 17.5% of revenue, driven by cost initiatives we announced in May and lower discretionary spending. Our adjusted operating margin for the quarter was 19.2%, up 390 basis points year-over-year, driven by lower costs due to cost control measures, lower infrastructure expenses and reduced discretionary spending. Our GAAP income tax rate for the quarter was 24.3%. Our adjusted EPS for the quarter was $1.04, up 23.8% year-over-year on a reported basis. During this pandemic period, liquidity and cash conservation remains a key priority. We exited the quarter with a very strong balance sheet. Our cash flow from operations for the quarter was $67.4 million, up from $58.2 million from the third quarter last year. Our DSO for the quarter was 57 days, down 6 days from the previous quarter and the lowest level during the past five years. We ended September with $363 million of cash and short-term investments and borrowings of $239 million, resulting in a net cash position of $124 million, up from $87 million at the end of the second quarter of this year. Now, moving to our nine-month performance. Our revenue for the period was $709.5 million, down 1.7% year-over-year. This decline was driven by COVID related supply and demand constraints, as mentioned earlier. Our adjusted operating margin for the period was 14.6%, down 20 basis points year-over-year, driven by lower revenues and net COVID related expense, partially offset by cost optimization initiatives. Adjusted EPS for the period was $2.39, up 3.9% year-over-year on a reported basis. In the first nine months of the year, we generated cash flow from operations of $126.3 million compared to $106 million for the same period last year. This reflects an effective implementation of our cash conservation strategy and efficient working capital management. During the first nine months of the year, we spent $34.6 million on capital expenditures as we continue to invest in the business for the long term. We expect our capital expenditures to be between $36 million and $38 million in 2020. Our effective tax rate for the first nine months of the year was 25%, and we expect the 2020 effective tax rate to be between 24.5% and 25%. We announced in mid-September that we intend to repurchase up to $80 million of our stock in 2020. During the first quarter, we repurchased $12 million of our shares. And in the third quarter, we repurchased $24.9 million of shares. Thus, we have repurchased 565,000 shares at an average purchase price of $65.25 during the first nine months of 2020. Now moving on to the outlook for the year. The economic environment remains unclear and business sentiment shifts given the nature of the pandemic. Thus, there are number of factors that we may not be able to predict accurately, but we feel more confident that our business model is resilient with better visibility into the fourth quarter and 2021. We are updating our revenue guidance for the year to be in the range of $950 million to $958 million, which is a $4 million increase at the midpoint, driven by better performance and increased visibility for the remainder of the year. Our updated guidance represents a year-over-year decline between 2% to 3% on a constant currency basis, excluding Health Integrated. Based on our updated guidance, we expect our fourth quarter revenue to range between $241 million and $249 million. Analytics should have a higher growth rate than operations management as the pipeline for expansions and new work can be implemented quicker to benefit fourth quarter revenue. Our updated guidance for adjusted EPS is for a range of $3.40 to $3.48, up $0.04 at the midpoint from previous guidance, driven by better third quarter performance. Based on our updated guidance, our fourth quarter adjusted EPS is expected to range between $1.01 and $1.09. In conclusion, we are pleased with our third quarter performance and our outlook for the remainder of the year. Our ability to quickly adapt to the economic changes brought about by the pandemic has benefited revenue growth since the trough in the second quarter and our efforts to manage our cost has resulted in a significant EPS improvement from a year ago on a lower revenue base. In the current uncertain economic environment, we feel we have the ability to quickly anticipate and adapt and can grow the business during this period. Now, Rohit and I would be happy to take your questions.